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ABSTRACT Despite the widespread use of antiretrovirals (ARV), more than 150,000
pediatric HIV-1 infections continue to occur annually. Supplemental strategies are nec-
essary to eliminate pediatric HIV infections. We previously reported that maternal
HIV envelope-specific anti-V3 IgG and CD4 binding site-directed antibodies, as well
as tier 1 virus neutralization, predicted a reduced risk of mother-to-child transmis-
sion (MTCT) of HIV-1 in the pre-ARV era U.S.-based Women and Infants Transmission
Study (WITS) cohort. As the majority of ongoing pediatric HIV infections occur in sub-
Saharan Africa, we sought to determine if the same maternal humoral immune cor-
relates predicted MTCT in a subset of the Malawian Breastfeeding, Antiretrovirals,
and Nutrition (BAN) cohort of HIV-infected mothers (n  88, with 45 transmitting
and 43 nontransmitting). Women and infants received ARV at delivery; thus, the ma-
jority of MTCT was in utero (91%). In a multivariable logistic regression model, nei-
ther maternal anti-V3 IgG nor clade C tier 1 virus neutralization was associated with
MTCT. Unexpectedly, maternal CD4 binding-site antibodies and anti-variable loop 1
and 2 (V1V2) IgG were associated with increased MTCT, independent of maternal vi-
ral load. Neither infant envelope (Env)-specific IgG levels nor maternal IgG transpla-
cental transfer efficiency was associated with transmission. Distinct humoral immune
correlates of MTCT in the BAN and WITS cohorts could be due to differences be-
tween transmission modes, virus clades, or maternal antiretroviral use. The associa-
tion between specific maternal antibody responses and in utero transmission, which
is distinct from potentially protective maternal antibodies in the WITS cohort, under-
lines the importance of investigating additional cohorts with well-defined transmis-
sion modes to understand the role of antibodies during HIV-1 MTCT.
KEYWORDS antiretrovirals, clade C HIV-1, humoral immunity, mother-to-child
transmission, peripartum transmission
The wide availability of maternal antiretroviral (ARV) therapy and infant prophylaxishas reduced the number of new HIV infections in infants by 70% between 2000 and
2015, making the rate of mother-to-child transmission (MTCT) of HIV less than 5% (1).
Nevertheless, more than 150,000 pediatric HIV-1 infections still occur annually due to
MTCT (1). Difficulties in adherence to ARV treatment, breakthrough transmission,
fetal/infant toxicities of ARVs, ARV-resistant HIV strains, and acute HIV infection of
mothers late in pregnancy and during the breastfeeding period all prevent the com-
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plete elimination of MTCT of HIV with ARVs. Additional prevention strategies, such as
maternal and/or pediatric vaccines, are needed to end the pediatric HIV epidemic.
Current HIV vaccination efforts have demonstrated the possible role of nonneutral-
izing antibodies in protection against HIV acquisition. For instance, the immune corre-
late analysis of the RV144 vaccine trial in Thailand revealed that higher levels of
antibodies against the variable loop 1 and 2 (V1V2) region of the glycoprotein gp120
(gp120) envelope protein, but not broad neutralization, were associated with protec-
tion against HIV-1 heterosexual transmission (2). The protective role of antibodies
against HIV-1 acquisition can also be studied in the setting of MTCT. In fact, there is
evidence that maternal and/or infant immune factors contribute to the relatively low
rate of MTCT, as the overall rate of MTCT in the absence of ARVs is between 30 and 40%,
with different transmission modes disparately contributing to this rate (20 to 30%
during pregnancy and delivery [perinatal transmission] and 10 to 15% via breastfeeding
[postnatal transmission]) (3).
To identify maternal immune responses responsible for this natural protection, our
group previously conducted a maternal humoral immune correlate analysis of MTCT
risk in a large cohort of U.S. clade B HIV-1-infected women (n  248) enrolled in the
pre-ARV era Women and Infants Transmission Study (WITS). After controlling for
well-known risk factors of infant HIV-1 acquisition, such as maternal virus load and
CD4 T cell counts, we observed an association between the neutralization of tier 1
(easy-to-neutralize) viruses, IgG antibodies against the envelope (Env) variable loop 3
(V3), and IgG antibodies against the CD4 binding site (bs) and decreased risk of MTCT.
Moreover, maternal V3-specific monoclonal antibodies were able to neutralize and
apply immune pressure on autologous virus strains, suggesting neutralization of au-
tologous viruses as a possible mechanism of this potential protection (4). Importantly,
previous studies have established that vaccination of HIV-1-infected individuals can
increase V3-specific and tier 1 virus-neutralizing responses and that V3-specific anti-
bodies can neutralize autologous virus strains, supporting the potential for maternal
vaccination to enhance protective maternal antibody responses as a way to prevent
MTCT of HIV (4–7).
Maternal antibodies are transferred to the fetus across the placenta, and fetal
plasma IgG levels at term can even exceed those of their mothers (4, 5). HIV Env-specific
antibodies could partially protect against HIV-1 transmission either by neutralizing/
impeding virus in maternal plasma prior to infant virus exposure or by protecting
infants upon virus exposure via passively acquired maternal antibodies. It is therefore
critical to assess the role of both maternal and infant transplacentally acquired anti-
bodies during HIV vertical transmission.
While studying the WITS cohort allowed the identification of immune factors associated
with reduced MTCT risk, it is important to note that this cohort is not the most
representative of current MTCT because (i) the WITS cohort was enrolled prior to the
availability of ARVs that are now widely used to prevent MTCT, and (ii) the study was
done in U.S. HIV-1-infected women who were infected with clade B strains of the
virus, whereas the overwhelming majority of infant HIV-1 infections occur in African
populations infected with clade C variants. Therefore, in this study, we sought to
determine the applicability of the maternal humoral immune correlates of MTCT risk
identified in the WITS to other MTCT settings, namely, in clade C virus-infected
African mother-infant pairs representative of the majority of ongoing pediatric HIV
infections. Using samples from the Malawian Breastfeeding, Antiretrovirals and
Nutrition (BAN) study (8), we investigated if commonly elicited Env-specific anti-
bodies are associated with reduced MTCT risk in this large cohort of clade
C-infected women who received ARVs around the time of delivery. This study
offered a unique opportunity to study how distinct MTCT transmission modes, HIV-1
clade, and ARV administration during delivery could influence immune correlates of
peripartum transmission of HIV-1.
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RESULTS
Plasma samples from 45 transmitting and 43 nontransmitting HIV-infected mothers
collected before delivery and from their corresponding infants from the Malawian BAN
study were studied. Table 1 provides clinical information regarding the mothers and
infants studied, including maternal viral load, CD4 T cell count, the timing of the visit
for the mother and infant pairs, and samples studied. Transmitting and nontransmitting
mothers were well matched by CD4 T cell count yet differed in median plasma viral
load (64,263 copies/ml for transmitting and 20,612 copies/ml for nontransmitting
mothers, P 0.02, Mann-Whitney U test; Table 1) and visit time points (antenatal versus
during labor/delivery) (P  0.03, Fisher’s exact test; Table 1). However, the previous
WITS established that the overwhelming majority of maternal antibody levels are stable
over several months and are not statistically significantly different among peripartum
time points (4). Meanwhile, infected and uninfected infant samples were similar by visit
number (i.e., at delivery, 2 weeks postdelivery, or 6 weeks postdelivery).
Primary analysis of maternal viral load and Env-specific maternal humoral im-
mune responses and their association with MTCT risk. We first assessed if maternal
viral load was predictive of MTCT risk, given that the transmitting mothers in our cohort
had a significantly higher maternal plasma viral load than the nontransmitting mothers
(P  0.02, Mann-Whitney U test) even after matching on maternal CD4 T cell count.
As previously observed (9–11), maternal plasma viral load significantly predicted peri-
partum MTCT risk (odds ratio [OR], 2.66; 95% confidence interval [CI], 1.25 to 5.66; P 
0.03) (Fig. 1A). Thus, all subsequent analyses and multivariable logistics regression
models were corrected for maternal plasma viral load as well as for CD4 T cell count.
Our analysis to determine if maternal anti-clade C V3 IgG CD4 binding-site (bs)-
blocking antibodies and clade C tier 1 neutralization were associated with risk of
peripartum MTCT in the clade C-infected BAN cohort revealed that neither anti-clade C
V3 IgG (OR, 0.57; 95% CI, 0.19 to 1.71; P  0.42) nor maternal plasma tier 1 virus
neutralization (OR, 1.37; 95% CI, 0.28 to 6.65; P  0.70) was associated with peripartum
MTCT risk (Table 2 and Fig. 1B and C). However, maternal plasma antibodies blocking
the CD4 bs were associated with an increased risk of MTCT, independent of maternal
plasma viral load (OR, 1.06; 95% CI, 1.02 to 1.10; P  0.03) (Table 2 and Fig. 1D and E).
Secondary analysis of maternal Env-specific maternal and infant humoral immune
responses and mother-infant transfer efficiency of IgG antibodies and their associa-
tion with MTCT risk. A secondary analysis was conducted to determine if any of the
other measured maternal or infant Env-specific antibody responses were associated
TABLE 1 Clinical characteristics of postmatching cohort of transmitting and nontransmitting HIV-1-infected mothers and corresponding
uninfected and infected infants from the BAN study
Variable Transmission status n
Median (interquartile range)
or percent SD P value
Mothers
Plasma viral load (copies/ml) Nontransmitters 43 20,612 (8,345–109,635) 115,457 0.02 (Mann-Whitney U test)
Transmitters 45 64,263 (20,036–196,620) 258,630
CD4 count (cells/l) Nontransmitters 43 367 (281–499) 166.6 0.90 (Mann-Whitney U test)
Transmitters 45 381 (278–497) 179.3
Visit
Antenatal Nontransmitters 43 100 0.03 (Fisher’s exact test)
Transmitters 39 86.7
Labor/delivery Nontransmitters 0 0
Transmitters 6 13.3
Infants
Visit
Delivery Uninfected 15 34.9 0.96 (chi-square test)
Infected 17 37.8
2 wk postdelivery Uninfected 24 55.8
Infected 24 53.3
6 wk postdelivery Uninfected 4 9.3
Infected 4 8.9
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with MTCT risk. These included maternal and infant binding antibodies against a
multiclade panel of Env antigens measured by binding antibody multiplex assay
(BAMA) and infant CD4 bs antibodies measured by blocking enzyme-linked immu-
nosorbent assay (ELISA). Maternal clade C V1V2-specific IgG level was significantly
associated with increased odds of peripartum MTCT, independent of maternal plasma
viral load (OR, 1.62; 95% CI, 1.08 to 2.44; P  0.04) (Table 3 and Fig. 2). The other tested
maternal antibody specificities (Table 3), infant Env-specific antibodies measured
against the same antigen panel used to measure maternal antibodies, infant clade C tier
1 neutralization, and infant CD4 bs-blocking antibodies were all not significantly
associated with peripartum MTCT. As most transmitted strains of HIV have a tier 2 (more
FIG 1 Maternal viral load and Env-specific maternal humoral immune responses and their association with MTCT risk. (A) Maternal viral load (OR, 2.66; 95% CI,
1.25 to 5.66; P  0.03) significantly predicted peripartum MTCT risk. (B and C) IgG-specific response in mothers to clade C V3 (V3.C) (OR, 0.57; 95% CI, 0.19 to
1.71; P  0.42) (B) and the magnitude of maternal tier 1 neutralization (SO032_A2.8-1) (OR, 1.37; 95% CI, 0.28 to 6.65; P  0.70) (C) were not associated with
peripartum MTCT risk. (D) Plasma blocking of soluble CD4-gp120 interactions (OR, 1.06; 95% CI, 1.02 to 1.10; P  0.03) was significantly associated with
peripartum MTCT risk. (E) Soluble CD4 plasma blocking and viral load are not correlated (r  0.04, P  0.7). Nontransmitting mothers are displayed in blue and
transmitting mothers in red.
TABLE 2 ORs of peripartum HIV-1 MTCT in primary immune correlates analysis using
multivariable logistic regression model
Humoral immune variable
Multivariable logistic regression
OR (95% CI)a
Uncorrected
P valueb
Corrected
P valueb
IgG binding to V3.C 0.57 (0.19–1.71) 0.32 0.42
Neutralization of tier 1 clade C virus SO032_A2.8-1 1.37 (0.28–6.65) 0.70 0.70
% CD4 bs blocking on clade C gp120
(1086C gp120)
1.06 (1.02–1.10) 0.003 0.03
aAdjusted for maternal CD4 T cell count and maternal viral load. 95% CI, 95% confidence interval.
bHumoral immune variable interactions with corrected P value of 0.05 are in bold font.
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difficult to neutralize) phenotype, we also measured maternal neutralization of two
clade C tier 2 viruses (CE1176_A3 and CE703010217_B6). There was no association
between maternal tier 2 virus neutralization and peripartum MTCT (OR, 1.20; 95% CI,
0.56 to 2.55; P  0.64 against CE1176_A3; and OR, 0.79; 95% CI, 0.33 to 1.91; P  0.64
against CE703010217_B6).
Association between maternal transplacental IgG transfer and MTCT risk. As
maternal HIV infection can interfere with the transplacental transfer of antibodies (12,
13), we measured the transfer efficiency of clade C gp120 (ConC gp120)-, V1V2-, and
V3-specific IgG in mother-infant pairs. We then sought to determine if transplacental
IgG transfer efficiency was associated with MTCT risk. For ConC gp120-, V1V2-, and
V3-specific IgG, infant IgG concentrations were significantly lower than their matched
maternal IgG levels (for ConC gp120, infant median, 577.4 g/ml versus maternal
median, 1,334 g/ml; for V1V2, infant median, 0.2 g/ml versus maternal median, 0.7
g/ml; for V3, infant median, 96.1 g/ml versus maternal median, 951.6 g/ml; P 
0.0001, Wilcoxon matched-pairs signed-rank test). Importantly, placental transfer effi-
ciency of IgG against consensus clade C gp120 (OR, 1.00; 95% CI, 0.98 to 1.01; P  0.79)
and against clade C V3 (OR, 0.99; 95% CI, 0.98 to 1.00; P 0.41) was not associated with
transmission risk. Interestingly, although there was a strong correlation between ma-
ternal and infant anti-V1V2-specific IgG concentration (r 0.93, P 0.0001, Spearman’s
rank correlation), anti-gp120-specific IgG concentration (r  0.81, P  0.0001), and
anti-V3-specific IgG concentration (r 0.81, P 0.0001), the transfer efficiency of clade
TABLE 3 ORs of peripartum HIV-1 MTCT for remaining maternal Env-specific humoral
immune responses (secondary analysis)
Antigen OR (95% CI)a
Uncorrected
P valueb
Corrected
P valueb
1086Cgp140 1.12 (0.55–2.28) 0.75 0.86
1086D7 gp120K160N 1.21 (0.58–2.52) 0.62 0.79
4403 BMC5 gp120 7.20 (0.96–54.07) 0.06 0.10
A244 gp120 gDneg/293F 1.93 (0.85–4.42) 0.12 0.19
B.con env03 gp140_CF 1.25 (0.57–2.73) 0.58 0.79
Bio-MPER656 1.27 (0.84–1.93) 0.26 0.40
Bio-V2.1086C 1.03 (0.71–1.51) 0.87 0.90
Bio-V2.B 1.07 (0.67–1.73) 0.78 0.86
Bio-V3.B 1.10 (0.60–2.01) 0.76 0.86
Con6gp120/B 3.04 (0.76–12.18) 0.12 0.19
ConC_gp120_WT 2.12 (0.83–5.39) 0.12 0.19
gp70 MNV3 0.90 (0.59–1.36) 0.61 0.79
gp70B.caseA V1V2/293F 1.51 (1.00–2.28) 0.05 0.10
gp70_B.caseA2_V1V2/169K 1.37 (0.94–2.00) 0.10 0.18
gp70_C.1086CV1/V2 1.62 (1.08–2.44) 0.02 0.04
aAdjusted for maternal CD4 T cell count and maternal viral load. 95% CI, 95% confidence interval.
bHumoral immune variable interactions with corrected P value of 0.05 are in bold font.
FIG 2 Comparison of anti-clade C V1V2 responses in HIV-1-infected transmitting and nontransmitting
mothers. IgG-specific response in mothers to clade C V1V2 (OR, 1.62; 95% CI, 1.08 to 2.44; P  0.04) was
significantly associated with peripartum MTCT risk. Nontransmitting women are displayed in blue (left)
and transmitting women in red (right).
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C V1V2-specific IgG did not predict transmission risk (OR, 1.00; 95% CI, 0.99 to 1.00; P 
0.67) despite the association between maternal V1V2-specific IgG and increased MTCT
risk. Thus, degree of HIV Env-specific IgG transfer from mother to infant did not predict
the risk of MTCT in this cohort of ARV-exposed clade C virus-infected mothers and their
infants.
DISCUSSION
In a previous humoral immune correlate analysis of MTCT risk using the WITS cohort,
common maternal clade B V3-specific IgG and CD4 bs antibody responses predicted a
decreased risk of peripartum MTCT (in utero plus intrapartum), while maternal tier 1
neutralization predicted a decreased risk of MTCT in the intrapartum cohort alone. We
therefore sought to determine if the same humoral immune factors predicted perinatal
MTCT risk in the African clade C HIV-1-infected BAN cohort of mothers and infants who
were given ARV prophylaxis around the time of delivery. Our results demonstrated that
clade C V3-specific IgG and maternal tier 1 virus neutralization were not associated with
peripartum transmission risk in the BAN cohort, although we acknowledge the confi-
dence interval for the odds ratio of maternal tier 1 virus neutralization is large, and that
confidence for this immune correlate is limited given the sample size. More surprisingly,
however, maternal anti-CD4 binding-site responses and clade C V1V2-specific IgG were
associated with increased odds of peripartum transmission independent of maternal
viral load.
The distinct humoral immune correlates of MTCT risk in the WITS and the BAN
mother-infant cohorts could be due to a number of differences between the two
cohorts. One of the most striking differences is the breakdown of mother-to-infant HIV
transmission modes. In the WITS cohort, which was conducted in the pre-ARV era, 13%
of MTCT occurred in utero, 52% occurred in the peripartum period, and 35% were
unknown due to the unavailability of nucleic acid HIV detection. In contrast, the
majority of MTCT in the BAN cohort was due to in utero transmission (91%). The high
proportion of in utero transmission in the BAN cohort is likely due to the fact that
women standardly received ARVs at delivery, which considerably reduced the propor-
tion of intrapartum transmission events. Another difference between the two cohorts
is the smaller available sample size for the BAN immune correlate analysis than that of
the WITS analysis, which is a limitation of our current study. Finally, the clade of HIV-1
infection is a major difference between the studies. While the WITS cohort consisted of
clade B HIV-1-infected women from the United States, the BAN cohort of women from
Malawi were infected with clade C HIV-1 strains. Interclade amino acid differences in
HIV Env glycoproteins can be as high as 35% and influence the genetic selection of
different viral strains and their interactions with their host’s immune response (14).
Importantly, previous studies have suggested that the mechanisms of in utero versus
intrapartum transmission differ in a number of ways. While in utero transmission occurs
transplacentally, intrapartum transmission occurs through infant exposure to maternal
secretions and blood, followed by infection of CD4 CCR5 T cells in the neonatal gut
during the delivery process (15). Dickover et al. described that mothers who transmitted
HIV-1 to their infants in utero were more likely to transmit one or multiple maternal
variants of HIV-1 that were dominant in maternal plasma, while intrapartum transmit-
ters were more likely to transmit minor maternal viral variants (16). This difference in
HIV-1 variants transmitted through the genetic bottleneck from mother to infant during
in utero versus intrapartum transmission might contribute to the difference in humoral
immune correlates associated with MTCT risk in the WITS and BAN cohorts.
The direct association between maternal V1V2-specific IgG antibodies and soluble
CD4 (sCD4)-blocking responses and MTCT risk in the BAN cohort was unexpected.
Although our small sample size might have contributed to these unexpected associa-
tions, tight confidence intervals increase the support for these correlates. Future studies
on larger populations will be important to confirm these findings and elucidate
whether these correlates have a mechanistic basis. It is possible that high levels of some
Env-specific antibodies may simply be a biomarker for increased viral infectivity of the
Mutucumarana et al. Clinical and Vaccine Immunology
August 2017 Volume 24 Issue 8 e00062-17 cvi.asm.org 6
 o
n
 August 13, 2019 at UNIVERSITY O
F NO
RTH CARO
LINA
http://cvi.asm
.org/
D
ow
nloaded from
 
dominant maternal variant. It is also possible that these nonneutralizing antibodies
bind to the HIV Env in vivo, change its conformation, and enhance its infectivity across
the placenta. However, this hypothesis needs to be tested with structural analysis to
address whether or not maternal antibodies may enhance placental transmission of
HIV-1 virions, and if so, how such antibody enhancement may occur. In addition,
although BAN participants were screened for serious infections prior to enrollment in
the study (8), it is possible that immune activation associated with coinfections, such as
cytomegalovirus (CMV), or comorbidities in mothers and infants that were not ac-
counted for could impact levels of maternal and/or infant plasma antibodies and/or the
risk of MTCT of HIV-1 and possibly influence the findings of this study. The immune
activation of placental membranes and secretion of proinflammatory cytokines into the
amniotic fluid during chorioamnionitis can increase localized HIV-1 replication in the
placenta and may increase in utero MTCT risk (17–20). In addition, maternal sexually
transmitted diseases (STDs) and cervical inflammation are associated with increased
intrapartum MTCT of HIV-1 (17, 21, 22). Unfortunately, peripheral blood mononuclear
cells (PBMCs) from this subset of patients were not available to test the possible role of
immune activation in MTCT in our study.
Interestingly, all significant humoral immune correlates of increased risk of MTCT
were observed in maternal plasma but not in infant plasma and were not associated
with transfer efficiency of Env-specific antibodies. Despite the association between high
maternal anti-V1V2 IgG and increased MTCT risk, the efficiency of the transplacental
transfer of anti-V1V2 IgG from mother to infant was not associated with increased MTCT
risk. This suggests that transplacental transfer of nonneutralizing IgG is not enhancing
MTCT by assisting with viral transmission across the placenta. Although some studies
have suggested that CMV virions may be transported across the placenta by coopting
receptors responsible for antibody transport across the placenta (23), our results do not
seem to support this type of scenario for peripartum mother-to-child transmission of
HIV-1. Despite the significantly lower infant Env-specific IgG levels than those of their
mothers, maternal gp120-, V1V2-, and V3-specific IgG levels were all strongly correlated
with the matched infant Env-specific IgG levels. Despite this correlation, infant IgG
responses at birth did not fully reflect maternal antibody responses, suggesting that
humoral immune correlate analyses of MTCT should be conducted in both mothers and
infants. Further studies of the infant immune correlates of MTCT may be important to
define which types of immune responses a potential pediatric HIV vaccine should elicit.
In the clade B virus-infected WITS cohort, maternal plasma clade B V3-specific IgG
was associated with transmission risk, whereas this association was not observed
between maternal plasma clade C V3-specific IgG in the clade C virus-infected BAN
cohort. One limitation of our study is that heterologous peptides, including the V3 loop
peptide, were used in binding assays to measure plasma antibody responses. However,
we attempted to select a clade C consensus V3 peptide that would be appropriate for
binding assays among a large collection of clade C HIV-1 strains from Malawian mothers
and infants. This approach is similar to the one used in the WITS in which IgG binding
to a clade B consensus V3 peptide was found to be associated with a reduced risk of
MTCT (4). Overall, using viral epidemiology signature pattern analysis (VESPA), 16/23
amino acids of the consensus clade C V3 peptide used in our assays were similar to
90% of 697 HIV envelope V3 sequences generated through single genome amplifi-
cation (SGA) from 19 clade C HIV-1-infected Malawian mother-infant pairs in a study by
Russell et al. (24) (see Fig. S1 in the supplemental material). Furthermore, studies of V3
among different clades have revealed that the clade C V3 domain is relatively more
conserved than that of clade B, as measured by the ratio of nonsynonymous to
synonymous substitutions in V3 (14). In addition, the amino acid motifs of a highly
conserved turn region of V3 differ between clades B and C (14). Clade C appears to be
less susceptible to anti-V3-mediated neutralization, suggesting that perhaps clade C V3
is less exposed on the Env trimer (14). Greater exposure of V3 on the Env trimer in clade
B viruses might explain why V3-specific antibodies are associated with decreased
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peripartum transmission risk in a clade B virus-infected cohort but not in a clade C
virus-infected cohort.
The surprising finding of an association of high levels of certain maternal plasma
Env-specific antibodies and in uteroMTCT risk in the BAN cohort adds to the complexity
of humoral immune correlates of protection against HIV-1 MTCT. In particular, this study
shows that there are differences in immune correlates associated either with risk of
peripartum MTCT between various transmission modes (in utero versus intrapartum)
and perhaps among different clades of HIV infection. Notably, further investigations
into interclade differences in the Env V1V2 loops and the CD4 binding site may aid in
explaining the distinct association between antibodies against these regions and MTCT
risk in the WITS and BAN cohorts. As over half of current infant HIV-1 infections occur
in sub-Saharan populations infected with clade C HIV (25), it is critical to study
additional clade C virus-infected cohorts to confirm the association we observed in the
BAN cohort. A study of clade C HIV-1-infected cohorts with a higher proportion of
intrapartum transmission cases would be useful to further shed light on humoral
immune correlates of distinct modes of MTCT. Further characterization of the role and
epitope specificity of maternal nonneutralizing antibodies associated with MTCT risk,
specifically the maternal clade C V1V2-specific IgG and sCD4 binding-site antibodies
found to be positively associated with peripartum MTCT risk in our study, would also
be useful. A clear definition of immune factors associated with protection against
peripartum MTCT risk will help define which immune responses should be elicited by
a vaccine that can assist in the elimination of pediatric HIV-1 worldwide.
MATERIALS AND METHODS
Study design. The BAN study conducted between 2004 and 2010 enrolled clade C HIV-1-infected
pregnant women from Malawi with a CD4 T cell count of 200 cells/l (8). All women and infants
received a single dose of nevirapine at the time of delivery, followed by 1 week of zidovudine (AZT) and
lamivudine. Women then breastfed for 24 to 28 weeks in the presence or absence of ARVs, depending
on randomization to the treatment or standard-of-care group.
Criteria for the selection of HIV-1-infected women from the BAN study for investigating humoral
immune correlates of peripartum transmission in the ARV era (Table 1) included nonheparin maternal
plasma samples available for immune assays from the third trimester of pregnancy, before delivery and
ARV administration, and corresponding infant plasma samples from infected infants (n 45). The control
group (n 45) of nontransmitting HIV-infected mothers and their corresponding uninfected infants were
selected based on similar characteristics and were matched only for maternal blood CD4 T cell count
with case samples, as maternal viral load was unavailable prior to study initiation. Infant plasma samples
were collected at delivery (n  34), 2 weeks postdelivery (n  48), or 6 weeks postdelivery (n  8). Two
samples from the nontransmitting group (one maternal and one infant) and their paired infant and
maternal data were excluded from analysis due to lack of adequate sample. Postmatching analysis of the
clinical characteristics of the transmitting and nontransmitting cohort revealed no significant difference
in peripheral CD4 T cell count (P  0.90, Mann-Whitney U test; Table 1) but a significant difference in
maternal plasma viral load (P  0.02, Mann-Whitney U test; Table 1). Because ARV administration
occurred per protocol around the time of delivery, the majority of MTCT in this subset of the BAN cohort
studied occurred in utero and not intrapartum (91% of HIV-infected infants in the HIV transmitting group
were infected in utero). Following the delivery window, all mother-infant pairs breastfed for 24 to 28
weeks and were assigned to one of three prophylaxis strategies: (i) maternal ARVs (zidovudine, lamivu-
dine, lopinavir, and ritonavir), (ii) daily infant ARV (nevirapine), or (iii) no ARV (control). In the cohort used
in this study, mothers from 38 mother-infant pairs received ARVs, infants from 27 pairs received
nevirapine, and in 25 pairs, neither the mother nor the infant received ARVs during breastfeeding.
The laboratory analyst performing all assays was blinded to the transmission status of maternal
samples and infection status of infant samples at the time of assays and data analysis.
Ethics statement. All adult study participants provided written informed consent for study partic-
ipation of themselves and their infants. Ethical approval for the BAN study was provided by the Malawi
National Health Science Research Committee and the institutional review boards at the University of
North Carolina at Chapel Hill and the U.S. Centers for Disease Control and Prevention.
HIV Env-specific IgG BAMA. HIV Env-specific binding IgG antibodies were measured by BAMA, as
previously described (2, 26), in maternal and infant plasma samples. A multiclade panel of primary and
consensus Env gp120 and gp140 antigens, V1V2 constructs, clade C V2 (KKKTELKDKKHKVHALFYKLDVVP),
V3 peptide (KKKNNTRKSIRIGPGQTFYATGDIIGDIRQAHC), and the membrane-proximal external region
(MPER) region of gp41 (KKKNEQELLELDKWASLWNWFNITNWLW) was tested (Table S1). Purified HIV-1
antigens were covalently coupled to carboxylated fluorescent beads (Bio-Rad, Hercules, CA). Antigen-
coupled beads were incubated with plasma at predetermined dilutions of the antigens listed in Table S1:
1:250 for 4403 BMC5 gp120, A244 gp120 gDneg/293F, 1086D7 gp120K160N, ConC_gp120_WT,
Con6gp120/B, 1086Cgp140, B.con env03 gp140_CF, gp70_C.1086CV1/V2, gp70B.caseA V1V2/293F,
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gp70_B.caseA2_V1V2/169K, Bio-V2.1086C, Bio-V2.B, Bio-V3.C, Bio-V3.B, gp70 MNV3, and Bio-MPER656
and 1:2,500 for clade C mutated gp120 (1086D7gp120K160N), clade C gp140, V3 peptide, and consensus
gp120. These dilutions were found to be within the linear range of the assay based on preliminary testing
of serial dilutions of five samples. IgG binding was detected with a phycoerythrin (PE)-conjugated mouse
anti-human IgG antibody (SouthernBiotech, Birmingham, AL) at 2 g/ml. Assay plates were read on a
Bio-Plex instrument (Bio-Rad, Hercules, CA), and the readout was expressed in mean fluorescence
intensity (MFI) units. Polyclonal HIV immunoglobulin (HIVIG) was used as a positive control for each assay
to ensure assay consistency, specificity, and reproducibility among assays on different dates. Blank beads
were included in every assay. The positivity cutoff for each antigen was determined as the average  3
standard deviations of MFIs of 30 HIV-seronegative samples tested at a 1:250 or 1:2,500 dilution. Preset
assay quality control criteria for reporting data included percent coefficient of variation (%CV) for
duplicate values 20%, 100 beads counted per well, and positive-control HIVIG titer within 3
standard deviations of the mean for each antigen, tracked with Levey-Jennings plots. The concentrations
of V3-, V1V2-, and consensus gp120-specific IgG antibodies were measured using specific antibodies as
standards (V1V2-specific monoclonal antibody CH58, V3-specific monoclonal antibody CH22, and gp120-
specific monoclonal antibody B12, generously provided by Barton Haynes).
HIV-1 neutralization assay. Neutralization assays were performed using heat-inactivated maternal
and infant plasma samples, as previously described (27), using Tat-regulated Luc reporter gene expres-
sion to quantify the reduction in viral infection of TZM-bl cells (NIH AIDS Reagent Program; contributed
by John Kappes and Xiaoyun Wu). Neutralization was measured against one clade C tier 1 “easy-to-
neutralize” Env-pseudotyped virus, SO032_A2.8-1 (GenBank accession no. KF114894), for both maternal
and infant samples. In addition, maternal samples were tested against two clade C tier 2 “difficult-to-
neutralize” Env-pseudotyped viruses, CE1176_A3 (GenBank accession no. FJ444437) and CE703010217_
B6 (GenBank accession no. FJ443575). These clade C tier 2 viruses were selected from a global panel
of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralization
antibodies to approximate the neutralizing activity seen against other clade C tier 2 subtype-
matched viruses as best as possible (28). Plasma was tested at eight 3-fold dilutions starting at 1:20.
The broadly neutralizing monoclonal antibodies B12 and VRC01 were used as positive controls.
Neutralization titer is reported as the dilution at which relative luminescence units (RLU) were
reduced by 50% compared to the RLU in the virus control well (50% inhibitory dose [ID50]). Plasma
samples were also tested for neutralization against a nonspecific murine retrovirus (MLV) to account
for any nonspecific neutralization activity. A plasma sample was considered positive for neutraliza-
tion if the ID50 against SO032_A2.8-1, CE1176_A3, or CE703010217_B6 was at least three times
higher than the ID50 of MLV.
Soluble CD4 plasma-blocking assay. Blocking of the binding of soluble CD4 on the HIV Env by IgG
was measured as described previously (2). Briefly, 384-well ELISA plates (VWR, Radnor PA) were coated
with 15 l of 2 g/ml HIV-1 Env 1086C gp120 (generously provided by the Duke Human Vaccine Institute
[DHVI] Protein Production Facility) diluted in 0.1 M sodium bicarbonate (30 ng/well) overnight. The plate
was washed once with phosphate-buffered saline (PBS)–0.1% Tween 20 prior to being blocked with 40
l of SuperBlock (PBS containing 4% whey protein–15% normal goat serum, 0.5% Tween 20) for at least
1 h at room temperature (RT). The plate was washed one time, and then 10 l of plasma samples diluted
1:50 in SuperBlock was incubated for 1 h at RT. The CD4 binding-site monoclonal antibody VRC01 was
used as a positive control. VRC01 was plated in a 2-fold dilution series starting at 32 g/ml. The plate was
washed 2 times, and then 10 l of soluble CD4 (sCD4; Progenics Pharmaceuticals, Inc.) was added at a
predetermined saturating concentration of 0.64 g/ml, incubated for 1 h at RT, and then washed 2 times.
The plate was then incubated with biotinylated anti-CD4 monoclonal antibody OKT4 (0.03 g/ml) for 1 h
at RT to detect sCD4 binding. The plate was washed 2 times and incubated with streptavidin horseradish
peroxidase (HRP; SouthernBiotech, Birmingham, AL) diluted at 1:30,000 in the dark for 1 h at RT. After a
4 washes, substrate (SureBlue Reserve microwell substrate; VWR, Radnor, PA) was added to the plate.
TMB (3,3=,5,5=-tetramethylbenzidine) stop solution (VWR) was added after a 10- to 15-min exposure time,
and the plate was immediately read at 450 nm with a plate reader. Background was subtracted from all
of the well absorbance readings and averaged for triplicate wells. Percent sCD4 plasma blocking was
calculated as: 100  (plasma triplicate mean/no plasma control mean)  100.
Statistical methods. The statistical analysis plan was finalized prior to data analysis. We used a
multivariable conditional logistic regression model that was adjusted for maternal plasma viral load and
peripheral CD4 T cell count, with transmission status as the dependent variable. Our primary analysis
applied multivariable logistic regression models for maternal clade C anti-V3 IgG response, tier 1 virus
neutralization, and sCD4 blocking percent inhibition. Secondary analyses included using logistic
regression models for each individual humoral immune response measured in the cohort, with the
dependent variable being transmission status for maternal samples or infection status for infant
samples. To account for alpha inflation from multiple comparisons, we applied the Benjamini-
Hochberg false-discovery rate correction (29) and reported the corrected P values. Corrected and
uncorrected P values can be found in Tables 1 to 3. We conducted a post hoc analysis to study the
impact of transplacental transfer from mother to infant of IgG antibodies against clade C V3, clade
C V1V2, and clade C consensus gp120 on MTCT. Transfer efficiency (%) was calculated according to
the following formula, where concentration refers to concentration of Env-specific IgG antibody as
determined from monoclonal antibody standards (concentrations are reported in micrograms per
milliliter): (infant concentration/maternal concentration)  100.
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Wilcoxon two-sample tests (Mann-Whitney U tests) were used to compare maternal viral load and
CD4 T cell count between transmitting and nontransmitting mothers. The correlation between infant
and maternal antibody concentrations was determined using Spearman’s rank correlation.
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